Pharmalucence gets FDA approval for generic Cardiolite

07/20/2009 | Mass High Tech (Boston)

The FDA gave radiopharmaceutical supplier Pharmalucence the green light to develop and market a generic version of Lantheus Medical Imaging's Cardiolite, a diagnostic imaging agent for coronary artery disease. Pharmalucence's product, the Kit for the Preparation of Technetium Tc-99m Sestamibi Injection, is used for identifying myocardial ischemia and infarction.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care